Restex

Quick links to important sections

Restex

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Restex

Property Description
Active ingredient Levodopa, Benserazide
Form Tablet, Capsule, Dispersible tablet
Pharmacological class Anti-Parkinsonian Agent
General purpose Management of Parkinsonism
Origin Synthetic compound

Restex: Defined as a Fixed-Dose Anti-Parkinsonian Agent

Restex is a prescription-only, fixed-dose combination product containing the two active ingredients, Levodopa and Benserazide, and is classified as an Anti-Parkinsonian Agent. This classification places it within the broader group of Dopaminergic Agents used specifically for the management of Parkinsonism. The use of this combination is clinically recognized across numerous countries as a primary pharmacological strategy to address mobility issues. Its fixed-dose nature is a key feature, ensuring that the two components are always administered together in the necessary proportion, a strategy supported by pharmacological research.

Composition, Origin, and Dosage Form

The core components, Levodopa and Benserazide, are formulated as synthetic compounds alongside pharmaceutical excipients. While Levodopa itself is a naturally occurring amino acid, the Benserazide component is synthetically produced. The preparation is designed for oral administration, with available dosage forms commonly including capsules, tablets, and dispersible tablets. Pharmacological literature confirms that Benserazide acts specifically as an Aromatic L-amino acid decarboxylase (AADC) inhibitor, a property central to the drug's design. This means the combination is chemically engineered to optimize the delivery of the primary active ingredient.

The Foundational Role of a Dopamine Precursor Combination

The general purpose of this medicine is to address the underlying deficiency of the neurotransmitter dopamine in the brain, which is responsible for the characteristic movement symptoms of Parkinsonism. Levodopa serves as the Dopamine precursor, providing the necessary raw material that the body utilizes to restore these depleted levels. The inclusion of Benserazide fundamentally enhances this process by preventing premature breakdown, thereby allowing more of the administered Levodopa to reach the brain intact. This scientifically validated combined strategy directly supports the relief of movement difficulties and the restoration of motor control.

What side effects are possible with Restex?

Possible Side Effects and Safety Information

The safety profile for the Levodopa/Benserazide combination is officially documented by regulatory authorities, classifying possible effects by frequency and the body system affected. These classifications organize the understanding of the medicine’s risk profile.

Frequency-Classified Adverse Reactions

The official labeling notes a range of reactions, with the most frequently observed effects generally classified as follows:

Classification Examples of Documented Effects
Very Common Dyskinesia (involuntary movements)
Common Nausea, vomiting, orthostatic hypotension, appetite disorders
Uncommon Cardiac arrhythmias, hallucinations, psychotic episodes
Rare Gastrointestinal bleeding, blood dyscrasias (e.g., hemolytic anemia)

Adverse reactions are formally grouped into System-Organ Classes (SOCs), including Nervous System Disorders, Psychiatric Disorders, Gastrointestinal Disorders, and Vascular Disorders.

Serious Adverse Reactions and Restrictions

Regulatory documents list certain risks classified as serious, such as Blood Dyscrasias and Hypersensitivity Reactions. The label also includes safety constraints based on pre-existing conditions. Use is officially contraindicated in individuals with known hypersensitivity to the components, as well as in patients with severe hepatic or renal impairment. Specific cautions are advised for use in individuals with existing cardiovascular disease or narrow-angle glaucoma.

Furthermore, the official safety documentation notes duration-specific patterns: motor fluctuations are associated with long-term exposure, while gastrointestinal effects are typically more noticeable at the start of treatment.

Overdose and Emergency Response

Overdose and when to seek help

Documented Overdose Manifestations

Official regulatory documents describe that overdose symptoms represent a significant increase in the severity of known adverse effects. Documented clinical manifestations primarily involve the cardiovascular and nervous systems. These include potentially severe changes in heart beat such as cardiac arrhythmias, pronounced abnormal involuntary movements (dyskinesia), and acute mental status changes characterized by confusion. Other effects listed in the regulatory profile are nausea, vomiting, and persistent insomnia. The potential for severe or life-threatening consequences is directly tied to the risk of cardiac arrhythmias.

Immediate Emergency Actions

Regulatory guidance strictly mandates that individuals seek immediate medical attention and go to a hospital straight away in the event of a suspected overdose. This requirement applies even if an individual, including those who may have taken the medicine by mistake, exhibits no immediate signs of discomfort. A procedural instruction is to always ensure the medicine packaging is taken along when seeking urgent care.

Officially Described Management

The management of an overdose is defined by the Necessity of Symptomatic and Supportive Care, as no specific antidote for Levodopa/Benserazide is listed in official prescribing information. Given the documented cardiovascular risks, hospital monitoring is required, often focusing on continuous cardiac function surveillance. This standardized approach is used to manage acute symptoms until the drug's effects have cleared the system.

Therapeutic Uses of Restex

What Restex Treats: Main Uses and Benefits

Restex is applied in conditions involving episodic or fluctuating manifestations, used in the symptomatic management of Parkinson's disease. The drug is indicated for the treatment of Parkinson's disease and related syndromes, including post-encephalitic parkinsonism. The medication is commonly used when supportive symptomatic management is appropriate, contributing to easing the overall symptom load.

Easing Core Movement Difficulties

This medication helps address the key motor symptoms related to increased neurological or muscular activity, such as muscle stiffness (rigidity), slowness of movement (bradykinesia), and tremor. It is applied in clinical settings that involve acute or unstable symptom patterns. The primary benefit is supportive relief, which may assist with maintaining functional stability when symptoms interfere with daily functioning.

Stabilizing Functional Consistency

Restex is relevant in conditions characterized by periods of heightened symptoms, particularly when symptoms interfere with functional stability, such as the unpredictable “on/off” periods of movement control common in advanced Parkinson's disease. It offers supportive therapeutic benefit by helping to promote a more consistent and stable capacity to move, assisting with maintaining functional stability and reducing the impact of symptom unpredictability on daily life.


Quick Fact: Relief for Motor Symptoms Restex is considered relevant in scenarios where symptoms escalate temporarily, offering supportive relief when symptoms interfere with routine activities.

Regulatory References

  1. DailyMed Carbidopa and Levodopa Label

Eligibility and Restrictions for Use

The eligibility for using Restex (Levodopa/Benserazide) is strictly defined by regulatory documents, which establish specific non-eligibility rules based on age, physiological state, and co-existing medical conditions.

Eligibility Scope

Category Official Regulatory Statement
Populations for whom use is allowed (as stated in label) Adults over the age of 25 years with Parkinson's syndrome (excluding drug-induced parkinsonism).
Populations for whom use is contraindicated Patients with known hypersensitivity to levodopa, benserazide, or excipients.
Patients taking non-selective Monoamine Oxidase (MAO) inhibitors.
Patients with closed-angle glaucoma or a history of malignant melanoma.

Age and Condition-Specific Eligibility

Category Official Regulatory Statement
Age-related eligibility rules Contraindicated in patients under 25 years of age as skeletal development must be complete.
Condition-specific eligibility rules Contraindicated in patients with decompensated endocrine function, severe cardiac disorders (e.g., severe arrhythmias), decompensated hepatic function, and decompensated renal function.
Pregnancy and lactation eligibility status Contraindicated for pregnant women or women of childbearing potential not using adequate contraception. Contraindicated during breastfeeding.

Connection to the overall eligibility profile: Official regulatory documents define non-eligibility based on absolute contraindications related to severe organ impairment, specific psychiatric or oncological conditions, and age of skeletal maturity. Use is also restricted for patients with certain cardiovascular conditions and those taking specific MAO inhibitors, as these limitations are explicitly documented in the official prescribing information.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The interaction profile for Restex (Levodopa/Benserazide) is defined by mandatory restrictions and cautions documented in regulatory sources.

Prohibited and High-Risk Combinations

Co-administration with Non-selective Monoamine Oxidase Inhibitors (MAOIs) is strictly contraindicated due to the high documented risk of a hypertensive crisis, requiring a formal washout period before Restex can be initiated.

Pharmacodynamic and Antagonistic Effects

  • Sympathomimetics: Co-administration may cause potentiation of cardiovascular effects, increasing the risk of cardiac events.
  • Antihypertensives: May lead to an additive hypotensive effect, which warrants monitoring.
  • Dopamine Antagonists (e.g., Phenothiazines): These agents are documented to antagonize the therapeutic effect of Levodopa.
  • General Anaesthetics (e.g., Halothane): Use is restricted due to the documented risk of cardiac arrhythmias.

Exposure and Timing Constraints

  • Iron Salts: Officially documented to significantly reduce Levodopa systemic exposure due to chemical binding. These agents must be separated by several hours during administration.
  • High-Protein Meals: The absorption (Cmax and AUC) of Levodopa is reduced and delayed due to competition for intestinal transport systems. Administration timing must account for this food-drug interaction to maintain consistent systemic exposure.
  • Other Anti-Parkinsonian Agents: Combining with other agents in this class may lead to a potentiation of existing effects.

Mechanism of Action

Central Synthesis of a Key Neurotransmitter

The core mechanism involves using Levodopa as a precursor molecule that passes through the Blood-Brain Barrier (BBB). Once inside the brain's motor centers, it is converted by the enzyme Aromatic L-amino acid decarboxylase (AADC) into dopamine. The resulting dopamine then acts as a natural agonist at post-synaptic Dopamine receptors, thereby initiating the required signaling cascades to facilitate functional neurotransmission and results in the physiological modulation of movement control.


Selective Protection and Optimized Central Delivery

The second component, Benserazide, acts as a competitive inhibitor of the AADC enzyme, but strictly in the peripheral circulation because it cannot cross the BBB. This selective peripheral action reduces the premature breakdown of Levodopa, leading to an increased amount of the intact precursor reaching the brain for central conversion. This synergistic process alters the mechanistic kinetics and optimizes the central bioavailability of the active compound.

Dosage and Administration Information

Official Administration Guidelines

Restex (levodopa/benserazide) is administered strictly by the oral route and follows specific protocols for dosing and timing.


Instruction Scope Official Labeled Usage
Route of Administration Oral only (tablet, capsule, or dispersible forms).
Dosing Schedule Initial dose: Treatment begins with a low, divided dose, typically 50 mg levodopa/12.5 mg benserazide or 100 mg levodopa/25 mg benserazide three to four times daily. Maintenance Dose: Gradually increased (titrated) until an effective individual dose is achieved. The typical daily levodopa component ranges between 300 mg and 800 mg, in divided doses.
Timing in Relation to Meals Optimally taken 30 minutes before or 1 hour after meals to support reliable absorption. Doses may be taken with a low-protein snack to manage initial gastrointestinal effects.
Preparation Requirements Dispersible tablets must be fully dissolved in a small amount of water (e.g., 25 mL to 50 mL) and consumed within 30 minutes of preparation. They must not be swallowed whole.
Age-Group Rules The medication is not indicated for patients who are under 25 years of age. Older adult patients may require a lower initial starting dose than standard adult patients.
Special Handling Modified-release capsules must be swallowed whole and must not be crushed or chewed to preserve the intended sustained-release profile. Treatment should be introduced and discontinued gradually.

Resulting Procedural Structure

The official instructions establish a procedure for gradual, fractional, and long-term oral administration. This protocol governs the correct timing of intake relative to food and mandates formulation-specific preparation steps to ensure the medication is used for its intended pharmacological effect.

Recent Clinical Evidence

Research Evidence Overview: Clinical Evaluation of Restex

This section summarizes the structure of the clinical studies and scientific reviews that inform the regulatory approval and use of Restex (Levodopa/Benserazide) for Parkinsonism. Studies help show what has been observed so far, providing context but not individual predictions.


Evidence for Symptomatic Management of Parkinson's Disease

Research involving Restex primarily uses short-term Randomized Controlled Trials (RCTs) to examine outcomes related to the core symptoms of Parkinson's disease. These studies explored measurements of outcomes related to physical discomfort and functional imbalance, focusing particularly on muscle stiffness (rigidity), slowness of movement (bradykinesia), and tremor. Short-term trials reported measurements of change in standardized motor rating scale scores in the observed populations compared to control groups. These findings describe patterns observed in the studies and indicate that the medicine was studied in research that examined movement difficulties.

Studies Examining Motor Function Stability and Fluctuations

Research also included studies applied in contexts involving fluctuating or unstable symptoms, a pattern seen in conditions characterized by episodic manifestations. These studies focused on patients who often experience unpredictable changes in their ability to move, sometimes referred to as "on/off" periods. Research examined outcomes capturing phases of heightened symptom activity, such as the amount of "on" time (periods when mobility is better) versus "off" time (periods when mobility is restricted). Studies monitored these outcomes to observe how measurements changed in the observed populations.

Long-Term Research and Follow-up Data

While short-term RCTs provide foundational information, long-term observational studies and patient registries have been used in research examining daily-life functioning. These studies follow patient groups over extended intervals, often up to five years or more. The evidence derived from these settings describes the overall patterns of functional status and the treatment approaches utilized by patients over time. However, long-term effects are not fully established by controlled trials, and there is limited information for long-term functional stability, which remains an area where more research is needed.

Research Gaps and Remaining Uncertainties

Scientific literature acknowledges several key limitations regarding the clinical evaluation of Restex. The follow-up durations were limited in many controlled trials. Furthermore, sample sizes were modest in some specialized studies, and evidence quality varies across studies, especially those examining complex motor fluctuations. These gaps highlight areas where research is ongoing and where data are still emerging.

Key Studies & References

  1. Levodopa-induced motor complications associated with benserazide and carbidopa in Parkinson's disease: a disproportionality analysis of the FAERS database
  2. Levodopa/carbidopa/entacapone versus levodopa/benserazide plus pramipexole in Chinese patients with Parkinson's disease experiencing wearing off
  3. Levodopa - Janusinfo.se (Environmental/Pharmacokinetic summary for Levodopa in Madopark)

Frequently Asked Questions (FAQ)

Common questions about Restex (FAQ)

Q: How quickly does Restex start working?

A: According to the official product information, the onset of action for immediate-release forms typically occurs within 30 to 60 minutes after taking a dose. The specific speed can depend on the medicine’s formulation; for instance, dispersible tablets may work faster, while controlled-release forms have a delayed start.


Q: How long do the effects of Restex last?

A: The official information indicates that the duration of effect for a standard, immediate-release dose generally lasts for about three to six hours. This duration can vary based on the specific type of tablet or capsule used and how the body processes the medication.


Q: What happens if I forget to take Restex?

A: Official guidance describes taking the dose once it is remembered. However, if it is almost time for the next scheduled dose, the product information advises skipping the missed dose. The label advises against doubling doses to compensate for a missed dose.


Q: Does Restex cause dependency?

A: The official administration protocol states that the medicine is introduced and discontinued gradually. Abruptly stopping or rapidly reducing the dose has been linked to a serious physical reaction resembling neuroleptic malignant syndrome (elevated temperature, confusion, muscular rigidity).


Q: Is it common to feel tired when taking Restex?

A: Official labeling documents note that excessive daytime sleepiness (somnolence) and episodes of suddenly falling asleep have been documented with levodopa treatment. The product information highlights this as a documented, potential effect.


Q: Can Restex be taken with over-the-counter pain relievers?

A: Official drug labels list specific, strong interactions with prescription medicines but typically do not list all over-the-counter (OTC) pain relievers. Decisions about combining medicines must be reviewed by a prescribing professional to check for compatibility.


Q: Does Restex interact with herbal supplements?

A: Official product information instructs patients to inform their healthcare professional about all concurrent treatments, including herbal supplements, traditional medicines, and herbal remedies. Regulatory information indicates that certain herbal supplements, such as St. John's Wort, may have documented interactions that could affect how the medicine works.


Q: Is Restex a controlled substance?

A: In many countries, this medicine is classified as a Prescription Only Medicine (POM). However, in countries like the US, the active ingredients (levodopa/benserazide) are typically not scheduled as a controlled drug or controlled substance.


Q: Does Restex carry a boxed warning?

A: Official regulatory documents for this class of medicine do not generally include the highest level of caution, often termed a 'boxed warning' in the US. However, the label does include other prominent warnings regarding risks such as falling asleep and potential psychiatric effects.


Q: Can Restex affect sleep patterns?

A: Sleep disturbances, such as insomnia (difficulty sleeping), are included on official lists of adverse reactions within the nervous system and psychiatric disorder categories.


Q: Is it normal to experience vivid dreams while taking Restex?

A: Official safety documents list hallucinations and psychotic episodes as documented adverse reactions. While not always listed separately, these psychiatric effects may involve vivid or disturbing dreams.


Q: Does Restex change how I react to alcohol?

A: Official interaction information suggests that consuming alcohol may increase certain nervous system side effects of levodopa. This may include intensifying effects such as dizziness, drowsiness, or difficulty concentrating.


Q: What is the legal classification of Restex in the US?

A: In the United States, the active ingredients are classified as a prescription-only drug. This means the medicine can only be obtained with a valid prescription from a licensed healthcare provider.


Q: What kind of monitoring is needed while taking Restex?

A: The official warnings and precautions sections specify that regular monitoring of key organ functions is required during treatment, including liver function, kidney function, and blood cell counts. Patients with a history of cardiovascular disease or glaucoma may also require close monitoring.


Q: Why is a prescription needed for Restex?

A: A prescription is required because the drug is used to manage a chronic, progressive neurological condition, has specific contraindications, carries risk of serious adverse effects (e.g., blood dyscrasias), and requires individualized dosing titration and medical monitoring.


Q: Where can I find the official patient information leaflet for Restex?

A: The official patient information leaflet (PIL) or Medication Guide is maintained and published by the national regulatory agencies in charge of drug licensing. These documents can typically be found on the websites of authorities such as the EMA, MHRA, or the equivalent national health authority where the product is licensed.


Q: Is it possible to develop tolerance to Restex over time?

A: Official safety information notes that with long-term treatment, motor complications such as 'wearing off' may develop. 'Wearing off' describes a reduction in the duration of a dose’s effectiveness, which is a pattern often managed by healthcare professionals.


Q: Is Restex the same type of medicine as [similar drug name]? (high-level comparison)

A: Restex is a combination drug, consisting of a dopamine precursor (Levodopa) and an enzyme inhibitor (Benserazide). This specific mechanism, which provides the brain with the raw material to create dopamine, differs from other anti-Parkinsonian agents, such as those that work by directly stimulating dopamine receptors (dopamine agonists).


Q: Does Restex affect appetite or weight?

A: Official lists of side effects commonly include appetite disorders, nausea, and vomiting, particularly when treatment is first started. Official safety documentation also lists changes in body weight as one of the generally reported adverse reactions.


Q: Are there any foods or drinks that should be avoided with Restex?

A: Official regulatory documents indicate that high-protein meals can reduce and delay the absorption of the levodopa component. Administration instructions regarding food timing are specified in the medicine's official label.


Q: Is Restex available as a generic medicine?

A: The combination of the two active ingredients, Levodopa and Benserazide, is available globally. While 'Restex' may be a specific brand name, the fixed-dose combination itself is widely available under various other brand names and generic names, such as Co-Beneldopa.


Q: Do studies suggest Restex improves quality of life?

A: The clinical trials that support the drug’s approval focus on evaluating its ability to improve the core motor symptoms of Parkinson's disease. The focus of these trials is on capturing changes in physical discomfort and functional imbalance, which describe observed patterns in mobility.


Q: Is Restex a brand name or a generic name?

A: The name 'Restex' is a brand name used for the fixed-dose combination of the two active, generic ingredients. The two generic active ingredients in the product are Levodopa and Benserazide.


Q: What are the main things Restex is not approved to treat?

A: Official documents define the conditions that the medicine is not indicated for. These include drug-induced parkinsonism, as well as certain other neurological conditions like Huntington's chorea and intention tremor.

How should Restex be stored and disposed of?

Storage Conditions

Restex (Levodopa/Benserazide) must be stored under specific conditions to maintain product stability. The medicine must not be stored above 25 C and should be maintained at or below this temperature, according to official regulatory labeling. Protection from moisture is required; therefore, the product must be kept in its original package with the container tightly closed.

Child Safety and Disposal

As a prescription medication, Restex must be securely stored. Regulatory documents mandate that the product be kept out of the sight and reach of children to prevent accidental ingestion or misuse.

For disposal, any unused or expired product must be discarded in accordance with local requirements. The official documentation specifies no special requirements concerning disposal as hazardous waste. Safe methods, such as utilizing a drug take-back program, are generally recommended.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Restex found in:

A-Z Index: